Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro
One of the most promising viral targets in current hepatitis B virus (HBV) drug development is the core protein due to its multiple roles in the viral life cycle. Here we investigated the differences in the mode of action and antiviral activity of representatives of six different capsid assembly mod...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[October 2018]
|
| In: |
Antiviral research
Year: 2018, Jahrgang: 158, Pages: 135-142 |
| ISSN: | 1872-9096 |
| DOI: | 10.1016/j.antiviral.2018.07.011 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.antiviral.2018.07.011 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0166354218303292 |
| Verfasserangaben: | Angelica Corcuera, Katharina Stolle, Stefan Hillmer, Stefan Seitz, Ji-Young Lee, Ralf Bartenschlager, Alexander Birkmann, Andreas Urban |
Search Result 1
Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro
Elsevier Science 2018 Universitätsbibliothek Heidelberg 2018
Article (Journal)
Online Resource